In a filing, Zentalis Pharmaceuticals Inc revealed its Director Myers Scott Dunseth acquired Company’s shares for reported $29373.0 on Apr 30 ’25. In the deal valued at $1.40 per share,21,000 shares were bought. As a result of this transaction, Myers Scott Dunseth now holds 281,192 shares worth roughly $0.38 million.
Then, Bruns Ingmar bought 20,000 shares, generating $45,656 in total proceeds. Upon buying the shares at $2.28, the Chief Medical Officer now owns 36,629 shares.
Before that, Cam Gallagher bought 687 shares. Zentalis Pharmaceuticals Inc shares valued at $1,374 were divested by the Former Director at a price of $2.00 per share.
Wedbush upgraded its Zentalis Pharmaceuticals Inc [ZNTL] rating to a Neutral from a an Underperform in a research note published recently. A number of analysts have revised their coverage, including UBS’s analysts, who decreased its forecast for the stock in mid June from “a Buy” to “a Neutral”. Wells Fargo also remained covering ZNTL and has decreased its forecast on June 18, 2024 with a “an Equal weight” recommendation from previously “an Overweight” rating. Wedbush revised its rating on June 18, 2024. It rated ZNTL as “an Underperform” which previously was an “a Neutral”.
Price Performance Review of ZNTL
On Friday, Zentalis Pharmaceuticals Inc [NASDAQ:ZNTL] saw its stock fall -8.22% to $1.34. Over the last five days, the stock has lost -11.84%. Zentalis Pharmaceuticals Inc shares have fallen nearly -55.78% since the year began. Nevertheless, the stocks have fallen -86.59% over the past one year. While a 52-week high of $9.92 was reached on 01/03/25, a 52-week low of $1.01 was recorded on 04/09/25.
Levels Of Support And Resistance For ZNTL Stock
The 24-hour chart illustrates a support level at 1.2900, which if violated will result in even more drops to 1.2400. On the upside, there is a resistance level at 1.4100. A further resistance level may holdings at 1.4800.
How much short interest is there in Zentalis Pharmaceuticals Inc?
A steep rise in short interest was recorded in Zentalis Pharmaceuticals Inc stocks on 2025-05-30, growing by 55165.0 shares to a total of 5.88 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-30 was 5.82 million shares. There was a rise of 0.94%, which implies that there is a positive sentiment for the stock.
